AU2015225954B2 - Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder - Google Patents

Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder Download PDF

Info

Publication number
AU2015225954B2
AU2015225954B2 AU2015225954A AU2015225954A AU2015225954B2 AU 2015225954 B2 AU2015225954 B2 AU 2015225954B2 AU 2015225954 A AU2015225954 A AU 2015225954A AU 2015225954 A AU2015225954 A AU 2015225954A AU 2015225954 B2 AU2015225954 B2 AU 2015225954B2
Authority
AU
Australia
Prior art keywords
hydroxypyridazin
ethyl
hydroxy
trifluoromethyl
pyridazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015225954A
Other languages
English (en)
Other versions
AU2015225954A1 (en
Inventor
Sarah Almond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50554599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015225954(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2015225954A1 publication Critical patent/AU2015225954A1/en
Application granted granted Critical
Publication of AU2015225954B2 publication Critical patent/AU2015225954B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2015225954A 2014-03-06 2015-03-06 Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder Ceased AU2015225954B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1403944.0A GB201403944D0 (en) 2014-03-06 2014-03-06 New use
GB1403944.0 2014-03-06
PCT/GB2015/050654 WO2015132608A1 (en) 2014-03-06 2015-03-06 Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder

Publications (2)

Publication Number Publication Date
AU2015225954A1 AU2015225954A1 (en) 2016-07-07
AU2015225954B2 true AU2015225954B2 (en) 2020-06-18

Family

ID=50554599

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015225954A Ceased AU2015225954B2 (en) 2014-03-06 2015-03-06 Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder

Country Status (32)

Country Link
US (1) US20170014407A1 (enExample)
EP (1) EP3113778B1 (enExample)
JP (1) JP6510549B2 (enExample)
KR (1) KR20160126081A (enExample)
CN (1) CN106102743A (enExample)
AU (1) AU2015225954B2 (enExample)
CA (1) CA2940342A1 (enExample)
CL (1) CL2016002151A1 (enExample)
CY (1) CY1120573T1 (enExample)
DK (1) DK3113778T3 (enExample)
EA (1) EA036438B1 (enExample)
ES (1) ES2676905T3 (enExample)
GB (1) GB201403944D0 (enExample)
GE (2) GEP20196984B (enExample)
HR (1) HRP20181082T1 (enExample)
IL (1) IL247435A0 (enExample)
LT (1) LT3113778T (enExample)
MA (1) MA39315A1 (enExample)
MX (1) MX2016010524A (enExample)
MY (1) MY202127A (enExample)
PH (1) PH12016501751A1 (enExample)
PL (1) PL3113778T3 (enExample)
PT (1) PT3113778T (enExample)
RS (1) RS57594B1 (enExample)
SG (1) SG11201607106YA (enExample)
SI (1) SI3113778T1 (enExample)
SM (1) SMT201800367T1 (enExample)
TR (1) TR201809537T4 (enExample)
TW (1) TW201534591A (enExample)
UA (1) UA123352C2 (enExample)
WO (1) WO2015132608A1 (enExample)
ZA (1) ZA201604611B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
PE20211761A1 (es) 2014-04-29 2021-09-07 Fmc Corp Herbicidas de piridazinona
TWI785022B (zh) 2017-03-28 2022-12-01 美商富曼西公司 新穎噠嗪酮類除草劑
BR112019028016B1 (pt) 2017-06-30 2023-12-05 Fmc Corporation Composto, composições herbicidas, mistura herbicida e método para controlar o crescimento de vegetação indesejada
CN112569217B (zh) * 2019-09-30 2022-04-22 厦门大学 戊酸衍生物在治疗遗传性小脑共济失调中的应用
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
EP4301367A1 (en) 2021-03-01 2024-01-10 Takeda Pharmaceutical Company Limited Use of luvadaxistat for the treatment of cognitive impairment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1084704B1 (en) * 1998-06-10 2006-03-29 Meiji Seika Kaisha Ltd. Remedies for spinocerebellar ataxia and compositions for treating spinocerebellar ataxia
AU2002339696A1 (en) * 2001-12-03 2003-06-17 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
JO3115B1 (ar) * 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao

Also Published As

Publication number Publication date
TR201809537T4 (tr) 2018-07-23
DK3113778T3 (en) 2018-07-30
WO2015132608A1 (en) 2015-09-11
CA2940342A1 (en) 2015-09-11
JP6510549B2 (ja) 2019-05-08
EA201691566A1 (ru) 2016-12-30
GB201403944D0 (en) 2014-04-23
PL3113778T3 (pl) 2018-11-30
SG11201607106YA (en) 2016-09-29
ZA201604611B (en) 2017-09-27
SI3113778T1 (en) 2018-08-31
AU2015225954A1 (en) 2016-07-07
LT3113778T (lt) 2018-08-27
EP3113778B1 (en) 2018-06-06
KR20160126081A (ko) 2016-11-01
CY1120573T1 (el) 2019-07-10
EA036438B1 (ru) 2020-11-11
US20170014407A1 (en) 2017-01-19
GEAP201914284A (en) 2019-02-25
TW201534591A (zh) 2015-09-16
MY202127A (en) 2024-04-05
PH12016501751A1 (en) 2017-02-06
CL2016002151A1 (es) 2016-12-30
ES2676905T3 (es) 2018-07-26
MA39315A1 (fr) 2017-09-29
PT3113778T (pt) 2018-07-11
RS57594B1 (sr) 2018-11-30
GEP20196984B (en) 2019-06-25
JP2017507156A (ja) 2017-03-16
HRP20181082T1 (hr) 2018-09-07
CN106102743A (zh) 2016-11-09
UA123352C2 (uk) 2021-03-24
IL247435A0 (en) 2016-11-30
MX2016010524A (es) 2016-10-31
SMT201800367T1 (it) 2018-09-13
EP3113778A1 (en) 2017-01-11

Similar Documents

Publication Publication Date Title
EP3113778B1 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
JP5675650B2 (ja) 向精神薬の働きを向上させるソルビン酸、安息香酸及びその誘導体
Stoker et al. Affective and somatic aspects of spontaneous and precipitated nicotine withdrawal in C57BL/6J and BALB/cByJ mice
JP5605659B2 (ja) 細胞保護剤
JP2012528818A (ja) Ｃｍｔ及び関連障害を処置するための新たな組成物
AU782492B2 (en) Method for the treatment of neurological or neuropsychiatric disorders
JP2022553371A (ja) α１Ａ－ＡＲ部分アゴニストを用いて神経障害を治療するための方法
EA023380B1 (ru) Комбинация пилокарпина и метимазола для лечения заболевания шарко-мари-тута и связанных с ним нарушений
WO2018200977A1 (en) Pimavanserin for treating impulse control disorder
EA017915B1 (ru) Kcnq-открыватели калиевых каналов, применяемые для лечения или ослабления симптомов шизофрении
Chen et al. Intra-cerebellar infusion of NMDA receptor antagonist AP5 disrupts classical eyeblink conditioning in rabbits
EA014576B1 (ru) Комбинированные препараты, содержащие бифепрунокс и l-допу
Doshi et al. Bilateral subthalamic nucleus stimulation for Parkinson's disease
Júnior et al. Effects of constant intravenous infusion of detomidine alone or combined with butorphanol or methadone for standing sedation in horses: a randomized clinical trial
Barr et al. Repeated electroconvulsive shock attenuates the depressive-like effects of d-amphetamine withdrawal on brain reward function in rats
TWI864376B (zh) 焦慮症處置用組成物及處置方法
HK1230925A1 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
US20080318926A1 (en) Methods of Treating Mood Disorders Using Pyridyloxymethyl and Benzisoxazole Azabicyclic Derivatives
WO2022079304A1 (en) Compositions and uses thereof
Vets et al. SAGI DENENBERG
Rizek et al. Management of Advanced Parkinson’s Disease
Cucuzella et al. Evaluation of sedative and analgesic effects of intravenous sub anesthetic doses of ketamine in horses
EP4208161A1 (en) Compositions and uses thereof
CN117899219A (zh) Htr1d作为靶点用于治疗疼痛-抑郁共病的药物中的应用
Coffman Role of the Serotonin 5HT 2c Receptor in Mediation of a Behavior that is a Potential Animal Model for OCD

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired